Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-27T09:43:36.630Z Has data issue: false hasContentIssue false

Serotonergic mechanisms and suicidal behavior

Published online by Cambridge University Press:  28 April 2020

H.M. van Praag*
Affiliation:
Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA
Get access

Summary

Disturbances in central serotonin (5-hydroxytryptamine, 5-HT) were first described in depression. They were inferred to exist based on the finding of lowered baseline and post-probenecid concentrations of 5-HIAA in CSF. Initially, depressed patients with and without deimonstrable disturbances in central 5-H1 seemed psychopathologically indistinguishable. Interpreting the available data, at that time, we introduced in 1971 the concept of biochemical heterogeneity of depression. Some forms, we postulated, are linked to disturbances in 5-HT functions, others are not or, to a much lesser extent. Subsequently, we showed the concept of a separate «5-HT depression» to be untenable. It seems more likely now that 5-HT disturbances in depression are not linked to a particular syndromal depression type, but to particular psychopathological dimensions, i.e. heightened anxiety and disturbed aggression regulation. These dimensions might form a prominent aspect of depression or may be virtually absent. They are moreover not specific for depression, but can occur in other psychiatric disorders as well. This might explain the seemingly capricious occurrence of 5-HT disorders in depression as well as their nosological non-specificity.

Based on the dimensional 5-HT hypothesis one might expect drugs that increase 5-HT availability in the brain to be effective in the various anxiety disorders, in depressions marked by increased anxiety and disturbed aggression regulation and in personality disorders with strong aggressive tendencies.

Résumé

Résumé

Des perturbations du fonctionnement du système sérotoninergique central ont tout d'abord été décrites chez des patients déprimés. Leur existence était inférée de la découverte de faibles concentrations basales de SHIAA dans te LCR après administration de probénècide. Initialement, les patients déprimés avec ou sans anomalies sérotoninergiques centrales semblaient indistinguables quant à la psychopathologie. Interprétant les données disponibles à cette époque, nous avons introduit en 1971 le concept d‘hétérogénéité biochimique de la dépression. Nous postulions que certaines formes de ce trouble étaient liées à des perturbations fonctionnelles sérotoninergiques, et que d'autres ne l'étaient pas ou l'étaient moins. Puis, nous avons montré que la notion d'une catégorie distincte «dépression sérotoninergique » ne correspondait pas à la réalité. Il apparaît plutôt que les perturbations sérotoninergiques associées aux états dépressifs ne sont pas liées à un type syndromique particulier, mais à des dimensions psychopathologiques, c'est-à-dire augmentation de l'anxiété et anomalies de la régulation de l‘agressivité. Ces dimensions peuvent former un aspect marquant de la dépression ou être virtuellement absentes. De plus, elles ne sont pas spécifiques de la dépression, mais peuvent survenir dans d'autres troubles psychiatriques. Cela pourrait expliquer l'apparence capricieuse de l‘occurrence des troubles sérotoninergiques dans la dépression, et leur non-spécificité nosologique. D'après cette hypothèse sérotoninergique dimensionnelle, il est possible d'espérer que des médicaments qui augmentent la disponibilité sérotoninergique puissent traiter efficacement des troubles anxieux variés, des dépressions marquées par ue forte angoisse des perturbations de la régulation de l’agressivité, et des troubles de la personnalité avec de fortes tendances agressives.

Type
Original article
Copyright
Copyright © European Psychiatric Association 1988

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Références

Asberg, M., Traskman, L. & Thoren, P. (1976) 5-HIAA in the cerebrospinal fluid: A biochemical suicide predictor? Arch. Gen. Psychiatr. 33, 11931197CrossRefGoogle ScholarPubMed
Asberg, M., Bertilsson, L., Martensson, B., Scalia-Tomba, G.P., Thoren, P. & Traskman, L. (1984) CSF monoamine metabolites in melancholia. Acta Psychiatr. Scand. 69, 201219CrossRefGoogle ScholarPubMed
Bioulac, B., Benezich, M., Renaud, B., Noel, B. & Roche, D. (1980) Serotonergic functions in the 47, XYZ syndrome. Biol. Psychiatry 15, 917923Google Scholar
Brown, G.L., Goodwin, F.K., Ballenger, J.C., Goyer, P.F. & Major, L.F. (1979) Aggression in humans correlates with cerebrospinal fluid metabolites. Psychiatr. Res. 1, 131139CrossRefGoogle Scholar
Brown, G.L., Ebert, M.E., Goyer, P.F., Jimerson, D.C., Klein, W.J., Bunney, W.E. & Goodwin, F.K. (1982) Aggression, sucide and serotonin: Relationships too CSF amine metabolites. Am. J. Psychiatry 139, 741746Google Scholar
Ceulemans, D.L.S., Hoppenbrouwers, M.I.J.A., Gelders, Y. & Reyntjens, A.J.M. (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: A double-blind placebo-controlled study versus lorazepam. Pharmakopsychiatry 18, 303305CrossRefGoogle ScholarPubMed
Den, Boer J.A., Westenberg, H.G.M., Kamerbeek, W.D.J., Verhoeven, W.M.A. & Kahn, R.S. (1987) Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int. Clin. Psychopharmacol. 2, 2132Google Scholar
Evans, L., Kenardy, J., Schneider, P. & Hoey, H. (1986) Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. Acta Psychiatr. Scand. 73, 4953CrossRefGoogle ScholarPubMed
Goodwin, F.V. & Post, R.M. (1983) 5-hydroxytryptamine and depression: A model for the interaction of normal variances and pathology. Br. J. Clin. Pharmacol. 15, 393405CrossRefGoogle Scholar
Kahn, R.S. & Westenberg, H.G.M. (1985) 1-5-Hydroxytryptophan in the treatment of anxiety disorders. J. Affect. Dis. 8, 197200CrossRefGoogle Scholar
Kahn, R.S., Westenberg, H.G.M. & Jolles, J. (1984) Zimelidine treatment of obsessive-compulsive disorder. Acta Psychiatr. Scand. 69, 259261CrossRefGoogle ScholarPubMed
Kahn, R.S., Westenberg, H.G.M., Verhoeven, W.M.A., Gispen-de-, Wied C.C. & Kamerbeek, W.D.J. (1987) Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int. Clin. Psychopharmacol. 2, 3345CrossRefGoogle ScholarPubMed
Kahn, R.S., Wetzler, S., Van, Praag H.M. & Asnis, G.M. (1988a) Indications of serotonergic supersensitivity in patients with panic disorder. Psychiatr. Res. (in press)CrossRefGoogle Scholar
Kahn, R.S., Van, Praag H.M., Wetzler, S., Asnis, G.M. & Barr, G. (1988b) Serotonin and anxiety revisited. Biol. Psychiatry 23, 189208CrossRefGoogle Scholar
Kahn, R.S., Wetzler, S., Van, Praag H.M. & Asnis, G.M. (1988c) Neuroendocrine evidence for 5-HT receptor hypersensitivity in patient with panic disorder. Psychopharmacol (in press)CrossRefGoogle Scholar
Koczkas, S., Holmberg, G., Wedin, L. (1981) A pilot study of the effect of the 5-HT uptake inhibitor, zimelidine, on phobic anxiety. Acta psychiatr. Scand. 63 (Suppl. 290), 328341CrossRefGoogle Scholar
Lidberg, L., Asberg, M., Sundquist-Stensman, U.B. (1984) 5-Hydroxyindoleacetic acid in attempted suicides who have killed their children. Lancet ii, 928CrossRefGoogle Scholar
Lidberg, L., Tuck, J.R., Asberg, M., Scalia-Tomba, G.P. & Bertilsson, L. (1985) Homicide, suicide and CSF 5-HIAA. Acta Psychiatr. Scand. 71, 230236CrossRefGoogle ScholarPubMed
Linnoila, M., Virkhunen, M., Scheinin, M., Nuutila, A., Rimon, R. & Goodwin, F.K. (1983) Low cerebrospinal fluid 5-hydroxyindoleacetie acid concentration differentiates impulsive from non impulsive violent behavior. Life Sci. 33, 26092614CrossRefGoogle Scholar
Taylor, D.P., Eison, M.S., Riblet, L.A. & Vandermaelen, C.P. (1985) Pharmacological and clinical effects of buspirone. Pharmacol. Biochem. Behav. 23, 687694CrossRefGoogle ScholarPubMed
Van Praag, H.M. (1982a) Depression, suicide and the metabolism of serotonin in the brain. J. Affect. Dis. 4, 275290CrossRefGoogle Scholar
Van Praag, H.M. (1982b) Neurotransmitters and CNS disease: Depression. Lancet ii, 12591264CrossRefGoogle Scholar
Van Praag, H.M. (1983) In search of the mode of action of antidepressants : 5-HT-tyrosine mixtures in depressions. Neuropharmacol. 22, 433440CrossRefGoogle ScholarPubMed
Van Praag, H.M. (1984) Studies in the mechanism of action of serotonin precursors in depression. Psychopharmacol. Bull. 20, 599602Google ScholarPubMed
Van Praag, H.M. (1986a) Biological suicide research. Outcome and limitations. Biol. Psychiatry 21, 13051323CrossRefGoogle Scholar
Van Praag, H.M. (1986b) Serotonin precursors with and wilhout tyrosine in the treatment of depression. In: Biological Psychiatry (Shagrass, C., Josias, R., Bridger, W., Weiss, K., Stoff, D. & Simpson, J. eds). New York, Elsevier Science Publishers Inc.Google Scholar
Van Praag, H.M. & Leijnse, B. (1965) neubewertung des syndroms. Skizze einer funktionollen pathologie. Psychiatr. Neurol. Neurochir. 68, 5066Google Scholar
Van Praag, H.M. & Korf, J. (1971) Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: a biochemical classification? Psychopharmacology 19, 148152CrossRefGoogle Scholar
Van Praag, H.M., Korf, J. & Puite, J. (1970) 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature 225, 12591260CrossRefGoogle ScholarPubMed
Van Praag, H.M., Korf, J., Lakke, J.P.W.F. & Schut, T. (1975) Dopamine metabolism in depression, psychoses and Parkinson's disease: the problem of the specificity of biological variables variables in behaviour disorders. Psychol. Med. 5, 138146CrossRefGoogle Scholar
Van Praag, H.M., Kahn, R., Asnis, G.M., Lemus, C.Z. & Brown, S.L. (1987a) Therapeutic indications for serotonin potentiating compounds. A hypothesis. Biol. Psychiatry 22, 205212CrossRefGoogle Scholar
Van Praag, H.M., Kahn, R., Asnis, G.M., Wetzler, S., Brown, S., Bleich, A. & Korn, M. (1987b) Denosologization of biological psychiatry on the specificity of 5-HT disturbances in psychiatric disorders. J. Affect. Dis. 13, 18CrossRefGoogle Scholar
Van Praag, H.M., Lemus, C. & Kahn, R. (1987c) Hormonal probes of central serotonergic activity. Do they really exist? Biol. Psychiatry 22, 8698CrossRefGoogle Scholar
Virkkunen, M., Nuutila, A., Goodwin, F.K. & Linnoila, M. (1987) Cerebrospinal fluid monoamine metabolite levels in male arsonists. Arch. Gen. Psychiatry 44, 241247CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.